Global Real World Evidence Solutions Market
Global Real World Evidence Solutions Market

Real World Evidence Solutions Comprehensive Study by Application (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, Others), End-User (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other), Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease, Other) Players and Region - Global Market Outlook to 2026

Real World Evidence Solutions Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 206 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Real World Evidence Solutions Market Scope?
Pharmaceutical companies spend a lot of time and money in the pre-authorization drug development stages, particularly in phase-III clinical trials, to provide solid evidence on their products' safety and efficacy. Such experiments are planned as Randomized Controlled Trials (RCTs), which are the gold standard for testing to prove the safety and effectiveness of a product of high validity but within clinical trial's tightly regulated boundaries. RCTs must be supplemented by the controversial new criterion known as Real-World Evidence (RWE). It is scientific evidence derived from real-world data about the use and possible benefits or risks of a medical product. Various research designs or evaluations, including but not limited to randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective), may produce RWE. It generates insight, foresight, and exploratory observations on diseases, goods, and patient populations using real-world data (RWD).The real-world evidence solution is being used to demonstrate the effectiveness of medications, vaccines, and other types of knowledge evidence. Furthermore, RWE is able to provide evidences based on real-world data. The widespread use of real-world evidence helps to improve healthcare quality, and RWD data on the effectiveness and safety of new drugs and medical devices can supplement RCT data.

The Real World Evidence Solutions market study is being classified, by Application (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Real World Evidence Solutions market throughout the predicted period.

IQVIA (United States), International Business Machines Corporation (IBM)(United States), ICON (Ireland), PAREXEL (United States), Syase (United States), Pharmaceutical Product Development (United States), Optum (United States), Clinigen Group (United Kingdom), Palantir Technologies (United Kingdom) and Flatiron Health (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Real World Evidence Solutions market by Type, Application and Region.

On the basis of geography, the market of Real World Evidence Solutions has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

May 2020 – Syapse, a San Francisco, CA-based provider of precision oncology solutions announced USD 30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC.


Influencing Market Trend
  • Delays in Drug Development and the Subsequent Increase in Development Costs

Market Drivers
  • Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
  • Shift From Volume- to Value-Based Care

Opportunities
  • Growth Opportunities in Emerging Markets
  • Rising Focus on End-To-End RWE Services

Restraints
  • Lack of Universally Accepted Methodological Standards and Data Processing Infrastructure

Challenges
  • Unwillingness to Rely on Real-world Studies


Key Target Audience
Hospitals and clinics, Pharmaceutical and Medical Device Manufacturing Companies, Academic Medical Centers, Government Research Organizations, Contract Research Organizations, Research and Consulting Firms and Regulatory Agencies

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Real World Evidence Solutions market expands?
The Global Real World Evidence Solutions market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Real World Evidence Solutions market?
The prominent players of Global Real World Evidence Solutions market are IQVIA (United States), International Business Machines Corporation (IBM)(United States), ICON (Ireland), PAREXEL (United States), Syase (United States), Pharmaceutical Product Development (United States), Optum (United States), Clinigen Group (United Kingdom), Palantir Technologies (United Kingdom) and Flatiron Health (United States), to name a few.

3. What are the top priorities to focus for Real World Evidence Solutions market’s growth?
In this highly competitive & fast evolving Real World Evidence Solutions industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Application
  • Claims Data
  • Clinical Settings Data
  • Patient-Powered Data
  • Pharmacy Data
  • Others
By End-User
  • Healthcare Payers
  • Healthcare Providers
  • Pharmaceutical & Medical Device Companies
  • Other

By Therapeutic Area
  • Oncology
  • Immunology
  • Neurology
  • Cardiovascular Disease
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
      • 3.2.2. Shift From Volume- to Value-Based Care
    • 3.3. Market Challenges
      • 3.3.1. Unwillingness to Rely on Real-world Studies
    • 3.4. Market Trends
      • 3.4.1. Delays in Drug Development and the Subsequent Increase in Development Costs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Real World Evidence Solutions, by Application, End-User, Therapeutic Area and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Real World Evidence Solutions (Value)
      • 5.2.1. Global Real World Evidence Solutions by: Application (Value)
        • 5.2.1.1. Claims Data
        • 5.2.1.2. Clinical Settings Data
        • 5.2.1.3. Patient-Powered Data
        • 5.2.1.4. Pharmacy Data
        • 5.2.1.5. Others
      • 5.2.2. Global Real World Evidence Solutions by: End-User (Value)
        • 5.2.2.1. Healthcare Payers
        • 5.2.2.2. Healthcare Providers
        • 5.2.2.3. Pharmaceutical & Medical Device Companies
        • 5.2.2.4. Other
      • 5.2.3. Global Real World Evidence Solutions by: Therapeutic Area (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Immunology
        • 5.2.3.3. Neurology
        • 5.2.3.4. Cardiovascular Disease
        • 5.2.3.5. Other
      • 5.2.4. Global Real World Evidence Solutions Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Real World Evidence Solutions: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. IQVIA (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. International Business Machines Corporation (IBM)(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ICON (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. PAREXEL (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Syase (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pharmaceutical Product Development (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Optum (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Clinigen Group (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Palantir Technologies (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Flatiron Health (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Real World Evidence Solutions Sale, by Application, End-User, Therapeutic Area and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Real World Evidence Solutions (Value)
      • 7.2.1. Global Real World Evidence Solutions by: Application (Value)
        • 7.2.1.1. Claims Data
        • 7.2.1.2. Clinical Settings Data
        • 7.2.1.3. Patient-Powered Data
        • 7.2.1.4. Pharmacy Data
        • 7.2.1.5. Others
      • 7.2.2. Global Real World Evidence Solutions by: End-User (Value)
        • 7.2.2.1. Healthcare Payers
        • 7.2.2.2. Healthcare Providers
        • 7.2.2.3. Pharmaceutical & Medical Device Companies
        • 7.2.2.4. Other
      • 7.2.3. Global Real World Evidence Solutions by: Therapeutic Area (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Immunology
        • 7.2.3.3. Neurology
        • 7.2.3.4. Cardiovascular Disease
        • 7.2.3.5. Other
      • 7.2.4. Global Real World Evidence Solutions Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Real World Evidence Solutions: by Application(USD Million)
  • Table 2. Real World Evidence Solutions Claims Data , by Region USD Million (2015-2020)
  • Table 3. Real World Evidence Solutions Clinical Settings Data , by Region USD Million (2015-2020)
  • Table 4. Real World Evidence Solutions Patient-Powered Data , by Region USD Million (2015-2020)
  • Table 5. Real World Evidence Solutions Pharmacy Data , by Region USD Million (2015-2020)
  • Table 6. Real World Evidence Solutions Others , by Region USD Million (2015-2020)
  • Table 7. Real World Evidence Solutions: by End-User(USD Million)
  • Table 8. Real World Evidence Solutions Healthcare Payers , by Region USD Million (2015-2020)
  • Table 9. Real World Evidence Solutions Healthcare Providers , by Region USD Million (2015-2020)
  • Table 10. Real World Evidence Solutions Pharmaceutical & Medical Device Companies , by Region USD Million (2015-2020)
  • Table 11. Real World Evidence Solutions Other , by Region USD Million (2015-2020)
  • Table 12. Real World Evidence Solutions: by Therapeutic Area(USD Million)
  • Table 13. Real World Evidence Solutions Oncology , by Region USD Million (2015-2020)
  • Table 14. Real World Evidence Solutions Immunology , by Region USD Million (2015-2020)
  • Table 15. Real World Evidence Solutions Neurology , by Region USD Million (2015-2020)
  • Table 16. Real World Evidence Solutions Cardiovascular Disease , by Region USD Million (2015-2020)
  • Table 17. Real World Evidence Solutions Other , by Region USD Million (2015-2020)
  • Table 18. South America Real World Evidence Solutions, by Country USD Million (2015-2020)
  • Table 19. South America Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 20. South America Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 21. South America Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 22. Brazil Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 23. Brazil Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 24. Brazil Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 25. Argentina Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 26. Argentina Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 27. Argentina Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 28. Rest of South America Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 30. Rest of South America Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 31. Asia Pacific Real World Evidence Solutions, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 34. Asia Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 35. China Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 36. China Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 37. China Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 38. Japan Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 39. Japan Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 40. Japan Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 41. India Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 42. India Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 43. India Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 44. South Korea Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 45. South Korea Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 46. South Korea Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 47. Taiwan Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 48. Taiwan Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 49. Taiwan Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 50. Australia Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 51. Australia Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 52. Australia Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 56. Europe Real World Evidence Solutions, by Country USD Million (2015-2020)
  • Table 57. Europe Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 58. Europe Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 59. Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 60. Germany Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 61. Germany Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 62. Germany Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 63. France Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 64. France Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 65. France Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 66. Italy Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 67. Italy Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 68. Italy Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 69. United Kingdom Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 71. United Kingdom Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 72. Netherlands Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 73. Netherlands Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 74. Netherlands Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 75. Rest of Europe Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 77. Rest of Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 78. MEA Real World Evidence Solutions, by Country USD Million (2015-2020)
  • Table 79. MEA Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 80. MEA Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 81. MEA Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 82. Middle East Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 83. Middle East Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 84. Middle East Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 85. Africa Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 86. Africa Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 87. Africa Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 88. North America Real World Evidence Solutions, by Country USD Million (2015-2020)
  • Table 89. North America Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 90. North America Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 91. North America Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 92. United States Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 93. United States Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 94. United States Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 95. Canada Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 96. Canada Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 97. Canada Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 98. Mexico Real World Evidence Solutions, by Application USD Million (2015-2020)
  • Table 99. Mexico Real World Evidence Solutions, by End-User USD Million (2015-2020)
  • Table 100. Mexico Real World Evidence Solutions, by Therapeutic Area USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Real World Evidence Solutions: by Application(USD Million)
  • Table 112. Real World Evidence Solutions Claims Data , by Region USD Million (2021-2026)
  • Table 113. Real World Evidence Solutions Clinical Settings Data , by Region USD Million (2021-2026)
  • Table 114. Real World Evidence Solutions Patient-Powered Data , by Region USD Million (2021-2026)
  • Table 115. Real World Evidence Solutions Pharmacy Data , by Region USD Million (2021-2026)
  • Table 116. Real World Evidence Solutions Others , by Region USD Million (2021-2026)
  • Table 117. Real World Evidence Solutions: by End-User(USD Million)
  • Table 118. Real World Evidence Solutions Healthcare Payers , by Region USD Million (2021-2026)
  • Table 119. Real World Evidence Solutions Healthcare Providers , by Region USD Million (2021-2026)
  • Table 120. Real World Evidence Solutions Pharmaceutical & Medical Device Companies , by Region USD Million (2021-2026)
  • Table 121. Real World Evidence Solutions Other , by Region USD Million (2021-2026)
  • Table 122. Real World Evidence Solutions: by Therapeutic Area(USD Million)
  • Table 123. Real World Evidence Solutions Oncology , by Region USD Million (2021-2026)
  • Table 124. Real World Evidence Solutions Immunology , by Region USD Million (2021-2026)
  • Table 125. Real World Evidence Solutions Neurology , by Region USD Million (2021-2026)
  • Table 126. Real World Evidence Solutions Cardiovascular Disease , by Region USD Million (2021-2026)
  • Table 127. Real World Evidence Solutions Other , by Region USD Million (2021-2026)
  • Table 128. South America Real World Evidence Solutions, by Country USD Million (2021-2026)
  • Table 129. South America Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 130. South America Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 131. South America Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 132. Brazil Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 133. Brazil Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 134. Brazil Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 135. Argentina Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 136. Argentina Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 137. Argentina Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 138. Rest of South America Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 139. Rest of South America Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 140. Rest of South America Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 141. Asia Pacific Real World Evidence Solutions, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 143. Asia Pacific Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 144. Asia Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 145. China Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 146. China Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 147. China Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 148. Japan Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 149. Japan Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 150. Japan Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 151. India Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 152. India Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 153. India Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 154. South Korea Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 155. South Korea Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 156. South Korea Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 157. Taiwan Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 158. Taiwan Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 159. Taiwan Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 160. Australia Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 161. Australia Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 162. Australia Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 166. Europe Real World Evidence Solutions, by Country USD Million (2021-2026)
  • Table 167. Europe Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 168. Europe Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 169. Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 170. Germany Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 171. Germany Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 172. Germany Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 173. France Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 174. France Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 175. France Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 176. Italy Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 177. Italy Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 178. Italy Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 179. United Kingdom Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 180. United Kingdom Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 181. United Kingdom Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 182. Netherlands Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 183. Netherlands Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 184. Netherlands Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 185. Rest of Europe Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 186. Rest of Europe Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 187. Rest of Europe Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 188. MEA Real World Evidence Solutions, by Country USD Million (2021-2026)
  • Table 189. MEA Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 190. MEA Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 191. MEA Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 192. Middle East Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 193. Middle East Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 194. Middle East Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 195. Africa Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 196. Africa Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 197. Africa Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 198. North America Real World Evidence Solutions, by Country USD Million (2021-2026)
  • Table 199. North America Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 200. North America Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 201. North America Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 202. United States Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 203. United States Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 204. United States Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 205. Canada Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 206. Canada Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 207. Canada Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 208. Mexico Real World Evidence Solutions, by Application USD Million (2021-2026)
  • Table 209. Mexico Real World Evidence Solutions, by End-User USD Million (2021-2026)
  • Table 210. Mexico Real World Evidence Solutions, by Therapeutic Area USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Real World Evidence Solutions: by Application USD Million (2015-2020)
  • Figure 5. Global Real World Evidence Solutions: by End-User USD Million (2015-2020)
  • Figure 6. Global Real World Evidence Solutions: by Therapeutic Area USD Million (2015-2020)
  • Figure 7. South America Real World Evidence Solutions Share (%), by Country
  • Figure 8. Asia Pacific Real World Evidence Solutions Share (%), by Country
  • Figure 9. Europe Real World Evidence Solutions Share (%), by Country
  • Figure 10. MEA Real World Evidence Solutions Share (%), by Country
  • Figure 11. North America Real World Evidence Solutions Share (%), by Country
  • Figure 12. Global Real World Evidence Solutions share by Players 2020 (%)
  • Figure 13. Global Real World Evidence Solutions share by Players (Top 3) 2020(%)
  • Figure 14. Global Real World Evidence Solutions share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 17. IQVIA (United States) Revenue: by Geography 2020
  • Figure 18. International Business Machines Corporation (IBM)(United States) Revenue, Net Income and Gross profit
  • Figure 19. International Business Machines Corporation (IBM)(United States) Revenue: by Geography 2020
  • Figure 20. ICON (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. ICON (Ireland) Revenue: by Geography 2020
  • Figure 22. PAREXEL (United States) Revenue, Net Income and Gross profit
  • Figure 23. PAREXEL (United States) Revenue: by Geography 2020
  • Figure 24. Syase (United States) Revenue, Net Income and Gross profit
  • Figure 25. Syase (United States) Revenue: by Geography 2020
  • Figure 26. Pharmaceutical Product Development (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pharmaceutical Product Development (United States) Revenue: by Geography 2020
  • Figure 28. Optum (United States) Revenue, Net Income and Gross profit
  • Figure 29. Optum (United States) Revenue: by Geography 2020
  • Figure 30. Clinigen Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Clinigen Group (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Palantir Technologies (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Palantir Technologies (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Flatiron Health (United States) Revenue, Net Income and Gross profit
  • Figure 35. Flatiron Health (United States) Revenue: by Geography 2020
  • Figure 36. Global Real World Evidence Solutions: by Application USD Million (2021-2026)
  • Figure 37. Global Real World Evidence Solutions: by End-User USD Million (2021-2026)
  • Figure 38. Global Real World Evidence Solutions: by Therapeutic Area USD Million (2021-2026)
  • Figure 39. South America Real World Evidence Solutions Share (%), by Country
  • Figure 40. Asia Pacific Real World Evidence Solutions Share (%), by Country
  • Figure 41. Europe Real World Evidence Solutions Share (%), by Country
  • Figure 42. MEA Real World Evidence Solutions Share (%), by Country
  • Figure 43. North America Real World Evidence Solutions Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • IQVIA (United States)
  • International Business Machines Corporation (IBM)(United States)
  • ICON (Ireland)
  • PAREXEL (United States)
  • Syase (United States)
  • Pharmaceutical Product Development (United States)
  • Optum (United States)
  • Clinigen Group (United Kingdom)
  • Palantir Technologies (United Kingdom)
  • Flatiron Health (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation